Your browser doesn't support javascript.
loading
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
Siu, Lillian; Brody, Joshua; Gupta, Shilpa; Marabelle, Aurélien; Jimeno, Antonio; Munster, Pamela; Grilley-Olson, Juneko; Rook, Alain H; Hollebecque, Antoine; Wong, Rebecca K S; Welsh, James W; Wu, Yuling; Morehouse, Christopher; Hamid, Oday; Walcott, Farzana; Cooper, Zachary A; Kumar, Rakesh; Ferté, Charles; Hong, David S.
Affiliation
  • Siu L; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ontario, Canada lillian.siu@uhn.ca.
  • Brody J; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
  • Gupta S; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio, United States.
  • Marabelle A; Drug Development Department, Gustave Roussy, Villejuif, France.
  • Jimeno A; Division of Medical Oncology, Department of Medicine, University of Colorado Denver, Denver, Colorado, United States.
  • Munster P; Department of Medicine (Hematology/Oncology), University of California San Francisco, San Francisco, California, United States.
  • Grilley-Olson J; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
  • Rook AH; Department of Dematology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
  • Hollebecque A; Drug Development Department, Gustave Roussy, Villejuif, France.
  • Wong RKS; Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
  • Welsh JW; Division of Radiation Oncology, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
  • Wu Y; AstraZeneca, Gaithersburg, Maryland, USA.
  • Morehouse C; AstraZeneca, Gaithersburg, Maryland, USA.
  • Hamid O; AstraZeneca, Gaithersburg, Maryland, USA.
  • Walcott F; AstraZeneca, Gaithersburg, Maryland, USA.
  • Cooper ZA; AstraZeneca, Gaithersburg, Maryland, USA.
  • Kumar R; AstraZeneca, Gaithersburg, Maryland, USA.
  • Ferté C; AstraZeneca, Gaithersburg, Maryland, USA.
  • Hong DS; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Immunother Cancer ; 8(2)2020 10.
Article in En | MEDLINE | ID: mdl-33037117
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stearic Acids / Antineoplastic Combined Chemotherapy Protocols / Heterocyclic Compounds, 3-Ring / Antibodies, Monoclonal / Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: J Immunother Cancer Year: 2020 Document type: Article Affiliation country: Canada Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stearic Acids / Antineoplastic Combined Chemotherapy Protocols / Heterocyclic Compounds, 3-Ring / Antibodies, Monoclonal / Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: J Immunother Cancer Year: 2020 Document type: Article Affiliation country: Canada Country of publication: United kingdom